Internal Medicine, Endocrinology, Diabetes, & Metabolism · Merrillville, IN
NPI
1528098506
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
6
Hospital affiliations
270 E 90th Dr Ste B
Merrillville, IN, 46410
Phone (219) 736-1758
Groups this clinician bills Medicare through
Medicare paid, 2024
$82K
2,334 services
Medicare patients, 2024
369
Average age 73
Drug cost, 2024
$4.9M
8,540 prescriptions
Company payments, 2025
$30K
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Nihad Muhrez was code 99214 (office e&m - established), 842 times for 341 patients. In total Nihad Muhrez billed 2,334 services in 8 codes, and Medicare paid $82K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-04-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 842 | 341 | $73.47 | $62K |
| 82962 Clinical Chemistry | Office | 705 | 252 | $3.14 | $2,217 |
| 83036 Blood Count | Office | 592 | 231 | $9.28 | $5,495 |
| 95251 Test - Miscellaneous | Office | 101 | 48 | $21.81 | $2,203 |
| 99215 Office E&M - Established | Office | 47 | 22 | $106.98 | $5,028 |
| 99205 Office E&M - New | Office | 37 | 37 | $125.38 | $4,639 |
By year: 2022 $105K for 2,840 services; 2023 $89K for 2,376 services; 2024 $82K for 2,334 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 705 | 252 | $3.14 | $2,217 |
| 83036 Blood Count | 592 | 231 | $9.28 | $5,495 |
Medicare prescription drug claims, 2024
In 2024, the drug Nihad Muhrez prescribed most often to Medicare patients was Levothyroxine Sodium, with 767 prescriptions and refills. In total Nihad Muhrez wrote 8,540 Medicare prescriptions that cost $4.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 767 | 2,111 | 202 | $7,351 |
| Metformin Hcl Generic | 749 | 2,171 | 247 | $3,883 |
| Ozempic Semaglutide | 569 | 1,059 | 159 | $1.0M |
| Mounjaro Tirzepatide | 462 | 753 | 102 | $804K |
| Jardiance Empagliflozin | 434 | 1,098 | 128 | $640K |
| Glimepiride Generic | 393 | 1,126 | 128 | $1,697 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 266 | 704 | 125 | $32K |
| Trulicity Dulaglutide | 215 | 494 | 79 | $489K |
| Farxiga Dapagliflozin Propanediol | 212 | 557 | 74 | $312K |
| Atorvastatin Calcium Generic | 182 | 544 | 52 | $1,429 |
| Synthroid Levothyroxine Sodium | 171 | 454 | 47 | $13K |
| Gabapentin Generic | 152 | 337 | 53 | $2,481 |
| Metformin Hcl Er Metformin Hcl | 138 | 395 | 52 | $1,247 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 130 | 333 | 59 | $27K |
| Humalog Kwikpen U-100 Insulin Lispro | 123 | 310 | 58 | $67K |
Brand drugs: 4,010 claims; generic drugs: 3,964 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Nihad Muhrez $30K ($30K in general payments such as food, travel and fees) from 23 companies. The largest payer was Lilly USA, LLC with $29K.
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC LLY | 67 | $29K |
| Novo Nordisk Inc NVO | 17 | $311 |
| Recordati_rare_diseases_inc. | 9 | $176 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 8 | $171 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 11 | $161 |
| Amgen Inc. AMGN | 7 | $159 |
| Xeris Pharmaceuticals, Inc. | 6 | $114 |
| Medtronic, Inc. MDT | 3 | $94.75 |
| Abbvie Inc. ABBV | 4 | $81.7 |
| Ascendis Pharma Endocrinology Inc ASND | 3 | $76.24 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.